+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dermatophytosis Treatment Market by Product Type, Drug Class, Distribution Channel, End User, Treatment Application - Global Forecast to 2030- Product Image
Dermatophytosis Treatment Market by Product Type, Drug Class, Distribution Channel, End User, Treatment Application - Global Forecast to 2030- Product Image
Sale

Dermatophytosis Treatment Market by Product Type, Drug Class, Distribution Channel, End User, Treatment Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967744
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Dermatophytosis Treatment Market grew from USD 13.33 billion in 2024 to USD 14.14 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 18.86 billion by 2030.

Unveiling the Dermatophytosis Treatment Landscape

Dermatophytosis, commonly known as fungal skin infections, represents a persistent challenge for healthcare providers and patients worldwide. As the prevalence of conditions such as athlete’s foot, jock itch, ringworm, and tinea versicolor continues to rise, stakeholders across the value chain must stay ahead of evolving treatment paradigms. This executive summary sets the stage by outlining the key drivers, obstacles, and emerging trends that define the current landscape.

At a time when drug resistance and patient compliance issues are increasingly spotlighted, the market for dermatophytosis therapies has become more dynamic than ever. New formulations, targeted drug classes, and digital health interventions are disrupting traditional approaches, creating both opportunities and complexities for pharmaceutical and biotechnology companies. Meanwhile, evolving regulatory frameworks and pricing pressures demand strategic agility and robust market intelligence.

This report synthesizes insights from industry experts, regulatory authorities, clinical practitioners, and patient advocacy groups to offer a multidimensional view of treatment innovations. By examining the interplay between product development, distribution channels, patient demographics, and regional dynamics, this introduction lays the groundwork for a deeper exploration of transformative shifts, tariff impacts, segmentation strategies, and actionable recommendations. Decision-makers can leverage these findings to chart a path toward sustainable growth and improved patient outcomes in the dermatophytosis treatment space.

Emerging Dynamics Shaping Therapeutic Approaches

The dermatophytosis market is undergoing a profound transformation driven by scientific breakthroughs and shifting patient expectations. In recent years, the focus has shifted from broad-spectrum antifungals to more targeted therapeutic classes, enabling clinicians to tailor interventions with greater precision and fewer adverse effects. This move toward personalized medicine is reinforced by advances in diagnostic technologies, which facilitate rapid identification of fungal strains and guide optimal treatment selection.

Regulatory bodies have also responded to the growing public health imperative by expediting approval pathways for novel formulations and combination therapies. These policy changes have incentivized collaboration between academic institutions and industry, accelerating the pipeline for high-potency allylamines and next-generation azoles. Concurrently, digital health platforms are empowering patients to adhere to prescribed regimens through remote monitoring and teleconsultation, reducing treatment abandonment and enhancing overall satisfaction.

Supply chain modernization further contributes to the evolving landscape. Real-time tracking, predictive analytics, and strategic receptor hubs are streamlining distribution, ensuring timely access to essential therapies. Together, these transformative forces are not merely incrementally improving the dermatophytosis treatment sector-they are redefining benchmarks for efficacy, safety, and patient engagement.

Navigating the Effects of New US Tariff Policies

The introduction of new United States tariff measures in 2025 has reverberated across the dermatophytosis treatment supply chain, compelling manufacturers and distributors to reassess sourcing strategies. Increased duties on key raw materials and finished goods have elevated production costs, prompting many players to explore alternative suppliers or localize manufacturing to maintain price competitiveness. As a result, partnerships with domestic API providers have gained traction, bolstering resilience against import-related uncertainties.

Beyond cost considerations, these tariffs have influenced pricing negotiations with payers and private healthcare providers. Faced with higher base costs, companies must now demonstrate enhanced value through clinical differentiation or improved patient outcomes. This regulatory shift underscores the importance of strategic procurement and supply chain diversification. Industry participants that proactively adjusted their logistics networks and leveraged regional manufacturing capabilities have mitigated margin erosion and preserved market access.

Ultimately, the 2025 tariff landscape serves as a pivotal case study in how external policy decisions can reshape competitive dynamics. By adopting agile sourcing practices and deepening relationships with domestic partners, stakeholders can navigate trade-related headwinds while sustaining innovation in the dermatophytosis treatment domain.

Insightful Segmentation to Decode Market Complexity

A granular segmentation analysis reveals the complex interplay of product types, drug classes, distribution channels, end-user settings, and treatment applications that define market dynamics. When considering product form, the oral category encompasses formulations such as capsules, suspensions and tablets, each offering unique advantages in systemic absorption and patient compliance. In contrast, the topical segment spans creams, gels, ointments and powders that deliver localized action with minimal systemic exposure.

Drug class segmentation highlights two primary mechanisms of action in the current therapeutic arsenal: allylamines, which inhibit ergosterol synthesis at early biosynthetic stages, and azoles, which target later enzymatic pathways to disrupt fungal cell membrane integrity. These distinct modes of delivery cater to varying clinical needs and resistance profiles.

Channel strategies further refine market access. Hospital pharmacies, whether private or public, serve as critical nodes for inpatient and outpatient prescriptions. Online pharmacies-facilitated through e-prescription platforms or over-the-counter offerings-enable remote fulfillment, while retail pharmacies, both chain networks and independent outlets, remain indispensable for broad community reach.

End-user segmentation underscores clinics-dermatology-focused or general-as first-line touchpoints, with homecare settings promoting patient autonomy and hospitals-public or private-managing severe or refractory cases. Overlaying these dimensions with treatment applications such as athlete’s foot, jock itch, ringworm and tinea versicolor sharpens the lens on unmet needs and growth levers across subpopulations.

Regional Trends Steering Treatment Adoption

Regional analysis illuminates divergent trajectories in the Americas, Europe Middle East & Africa and Asia-Pacific, each shaped by distinct regulatory environments, healthcare infrastructures and epidemiological patterns. In the Americas, robust reimbursement frameworks and concentrated dermatology networks drive high adoption rates of advanced formulations. Patient awareness campaigns and teledermatology services further enhance treatment penetration across both urban centers and underserved regions.

Conversely, Europe Middle East & Africa presents a mosaic of regulatory harmonization efforts alongside localized approval processes. While established markets prioritize formulation innovation and patient support programs, emerging economies within this region are witnessing increased demand for cost-effective generics and public health interventions to combat fungal outbreaks.

Asia-Pacific stands out as a high-growth arena, propelled by expanding urban populations, rising disposable incomes and heightened healthcare expenditure. Local manufacturers are scaling production of both branded and generic therapies, while multinational companies establish joint ventures to navigate complex market entry conditions. Across all regions, digital health and telemedicine adoption is forging new pathways for patient engagement and remote care delivery.

Competitive Forces Driving Industry Progress

The competitive landscape features a diverse mix of global pharmaceutical leaders, specialized biotech firms and agile generics manufacturers, all vying to differentiate through pipeline innovation, strategic alliances and market access excellence. Established corporations leverage extensive R&D budgets to advance next-generation antifungal candidates and secure orphan drug designations for refractory dermatophytosis variants, while emerging players focus on niche segments and rapid commercialization cycles.

Collaborations between academic research centers and commercial entities are catalyzing breakthroughs in novel drug delivery technologies, including microemulsions and nanoparticle carriers designed to enhance tissue penetration and reduce systemic toxicity. Meanwhile, generic producers are intensifying cost-efficiency measures to remain competitive amid pricing pressures, often pursuing licensing agreements or co-promotion partnerships to expand their geographic reach.

In parallel, a wave of mergers and acquisitions underscores the sector’s drive toward scale and diversification. Companies with complementary portfolios are forging alliances to streamline logistics, maximize cross-selling opportunities and achieve operational synergies. These strategic moves are redefining market hierarchies and setting the stage for a more consolidated, innovation-focused dermatophytosis treatment ecosystem.

Strategic Imperatives to Enhance Market Performance

To capitalize on evolving market dynamics, industry leaders should prioritize investment in differentiated formulations that address emerging resistance patterns and enhance patient adherence. Establishing flexible supply chain frameworks that integrate regional manufacturing hubs will mitigate the impact of trade policy fluctuations and ensure uninterrupted product availability.

Enhancing digital patient engagement through mobile applications and telehealth platforms can drive higher treatment initiation and completion rates, particularly in hard-to-reach populations. Simultaneously, tailored education programs for healthcare professionals and patient communities will reinforce best practices and support market adoption of novel therapies.

Strategic collaborations with payers and health authorities will facilitate value-based contracting models, demonstrating cost-effectiveness and securing favorable formulary placements. Additionally, a targeted approach to market entry-aligned with regional regulatory requirements and reimbursement landscapes-will optimize resource allocation and accelerate time to revenue. By embracing these actionable imperatives, companies can strengthen their competitive positioning and deliver tangible improvements in patient outcomes.

Rigorous Analytical Framework Underpinning Findings

This analysis is underpinned by a rigorous methodology combining primary research with comprehensive secondary data synthesis. In-depth interviews with key opinion leaders, industry executives and clinical specialists provided nuanced perspectives on therapeutic innovations and market access dynamics. Concurrently, proprietary databases, regulatory filings and peer-reviewed publications were scrutinized to validate trends and benchmark corporate strategies.

A multi-step data triangulation approach ensured consistency and reliability, with cross-validation from regional experts and third-party sources confirming the robustness of segmentation and competitive assessments. Qualitative insights were augmented by thematic analysis, identifying emerging patterns in product development, distribution evolution and patient engagement techniques.

Throughout the research process, stringent quality control protocols- including iterative peer reviews and data integrity checks-maintained analytical rigor and minimized potential bias. This methodological foundation delivers an authoritative, actionable portrayal of the dermatophytosis treatment market, equipping decision-makers with the insights needed to navigate this complex and evolving domain.

Consolidating Insights for Informed Decision Making

The dermatophytosis treatment landscape is at a pivotal juncture, characterized by scientific innovation, shifting regulatory terrain and dynamic patient expectations. By weaving together segmented insights across product types, drug classes, channels, end users and treatment applications, this report illuminates the critical levers that will shape future growth.

Tariff policy shifts in the United States underscore the necessity for agile supply chain strategies, while regional variations highlight the importance of tailored market entry and distribution approaches. Competitive analysis reveals a sector in motion, driven by collaboration, consolidation and a relentless focus on pipeline advancement.

Collectively, these findings call for a balanced approach that harmonizes R&D investment with pragmatic market access initiatives, digital engagement and strategic partnerships. As industry participants prepare for the next phase of transformation, the insights presented here provide a clear roadmap for capturing value and delivering improved patient outcomes in the fight against dermatophytosis.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Oral
      • Capsules
      • Suspensions
      • Tablets
    • Topical
      • Creams
      • Gels
      • Ointments
      • Powders
  • Drug Class
    • Allylamines
    • Azoles
  • Distribution Channel
    • Hospital Pharmacies
      • Private
      • Public
    • Online Pharmacies
      • E Prescription
      • OTC
    • Retail Pharmacies
      • Chain
      • Independent
  • End User
    • Clinics
      • Dermatology Clinics
      • General Clinics
    • Homecare
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Treatment Application
    • Athlete's Foot
    • Jock Itch
    • Ringworm
    • Tinea Versicolor
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • GlaxoSmithKline plc
  • Bayer AG
  • Johnson & Johnson
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Lupin Limited
  • Viatris Inc.
  • Torrent Pharmaceuticals Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dermatophytosis Treatment Market, by Product Type
8.1. Introduction
8.2. Oral
8.2.1. Capsules
8.2.2. Suspensions
8.2.3. Tablets
8.3. Topical
8.3.1. Creams
8.3.2. Gels
8.3.3. Ointments
8.3.4. Powders
9. Dermatophytosis Treatment Market, by Drug Class
9.1. Introduction
9.2. Allylamines
9.3. Azoles
10. Dermatophytosis Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Private
10.2.2. Public
10.3. Online Pharmacies
10.3.1. E Prescription
10.3.2. OTC
10.4. Retail Pharmacies
10.4.1. Chain
10.4.2. Independent
11. Dermatophytosis Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.2.1. Dermatology Clinics
11.2.2. General Clinics
11.3. Homecare
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Dermatophytosis Treatment Market, by Treatment Application
12.1. Introduction
12.2. Athlete's Foot
12.3. Jock Itch
12.4. Ringworm
12.5. Tinea Versicolor
13. Americas Dermatophytosis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Dermatophytosis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Dermatophytosis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. GlaxoSmithKline plc
16.3.3. Bayer AG
16.3.4. Johnson & Johnson
16.3.5. Sanofi SA
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Lupin Limited
16.3.9. Viatris Inc.
16.3.10. Torrent Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DERMATOPHYTOSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. DERMATOPHYTOSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. DERMATOPHYTOSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DERMATOPHYTOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DERMATOPHYTOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DERMATOPHYTOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ALLYLAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY E PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CHAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ATHLETE'S FOOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY JOCK ITCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RINGWORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TINEA VERSICOLOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 77. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 78. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 81. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 82. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 83. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 85. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 86. CANADA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 90. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 93. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 94. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 95. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 151. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 155. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 162. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 163. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 166. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 167. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 168. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 170. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 186. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 187. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 188. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 190. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 191. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 192. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 194. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. ITALY DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 198. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 199. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 202. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 203. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 204. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 247. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 250. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 252. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 270. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 271. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 272. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 274. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 275. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 276. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 279. QATAR DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 282. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 283. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 286. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 287. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 288. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 290. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 291. FINLAND DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 304. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TREATMENT APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 318. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 319. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 320. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 322. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 323. EGYPT DERMATOPHYTOSIS TREATMENT MARKET SIZE, BY RETAIL PHA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dermatophytosis Treatment market report include:
  • Novartis AG
  • GlaxoSmithKline plc
  • Bayer AG
  • Johnson & Johnson
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Limited
  • Lupin Limited
  • Viatris Inc.
  • Torrent Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 14.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.86 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dermatophytosis Treatment Market Report 2025 - Product Image

Dermatophytosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Natural Products for Treatment of Skin and Soft Tissue Disorders - Product Image

Natural Products for Treatment of Skin and Soft Tissue Disorders

  • Book
Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Dermatological Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Seborrheic Dermatitis Treatment Market by Formulation, Treatment Type, Distribution Channel, Drug Class, Product Type - Global Forecast to 2030 - Product Image

Seborrheic Dermatitis Treatment Market by Formulation, Treatment Type, Distribution Channel, Drug Class, Product Type - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Skin Allergy Therapeutics Market by Therapeutic Class, Treatment Type, Application Type, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030 - Product Image

Skin Allergy Therapeutics Market by Therapeutic Class, Treatment Type, Application Type, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From

About the Dermatophytosis Drug Market

Dermatophytosis is a fungal infection of the skin, hair, and nails caused by dermatophytes. Dermatophytosis drugs are used to treat this condition. These drugs are typically antifungal medications, such as terbinafine, itraconazole, and fluconazole. They are available in both topical and oral forms. In addition, some dermatophytosis drugs are used to treat other fungal infections, such as candidiasis and tinea versicolor. The dermatophytosis drug market is a subset of the larger dermatological drug market. It is composed of a variety of products, including antifungal medications, topical creams, and ointments. These products are used to treat a range of fungal infections, including dermatophytosis. Some companies in the dermatophytosis drug market include Pfizer, Novartis, Merck, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.